Maribavir Form VI Crystallization for Higher-Yield Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing syntheses of maribavir, an antiviral medication for cytomegalovirus, suffer from low overall yields and impurity issues, which affect the quality and safety of the drug product.
Innovation Solution
An improved synthesis of maribavir is developed, involving specific modifications to reaction conditions and purification methods to enhance yield and minimize impurities, particularly through controlled crystallization and formulation into a particular polymorphic form (Form VI) with targeted particle size distributions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing synthesis methods (U.S. Pat. No. 6,077,832 or WO 2001/077083) are used, then maribavir can be produced, but the overall yield is low (27% or 18-20%) and impurities are generated
Solution Approach 1:
The patent modifies reaction parameters including solvent selection (acetonitrile instead of conventional solvents), temperature control (reflux conditions), and stoichiometry (specific equivalents of reagents) to improve both yield and purity. The crystallization parameters are also optimized to enhance product quality while minimizing impurities.
Solution Approach 2:
The patent converts the harmful effect of impurity formation during synthesis into a beneficial outcome by implementing a crystallization step that selectively purifies the product. The impurities generated in the reaction are separated during crystallization, allowing high-purity maribavir to be obtained despite the complex multi-step synthesis.
2Ease of manufacture
If multiple chemical transformation steps are performed, then maribavir can be synthesized, but the process complexity increases and yield decreases
Solution Approach 1:
The patent combines multiple synthesis steps into a streamlined sequence where intermediates are carried forward without isolation when possible. The coupling reaction, deprotection, and crystallization steps are optimized to occur in sequence with minimal handling, reducing cumulative yield loss while maintaining manufacturing feasibility.
Solution Approach 2:
The patent performs preliminary protection of functional groups (acetyl protection of hydroxyl groups) before the main coupling reaction to prevent side reactions. This preliminary action ensures that the subsequent steps proceed cleanly with higher yields and fewer impurities requiring complex purification.
3Reliability
If purification methods are applied to reduce impurities, then drug quality improves, but manufacturing time and complexity increase
Solution Approach 1:
The patent utilizes phase transition through crystallization as the primary purification method. By controlling the dissolution and crystallization of maribavir from acetonitrile solution, high-purity product is obtained in a single operation that simultaneously concentrates the product and excludes impurities, avoiding complex chromatographic or extraction procedures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The improved synthesis achieves yields of at least 45% and produces maribavir with reduced impurities, ensuring consistent drug quality and safety for oral formulations.
Implementation Method 1
The synthesis of maribavir is described in Examples 1, 2, and 5 of U.S. Pat. No. 6,077,832. This synthesis, depicted in Scheme 1 below, consists of three chemical transformation steps with a combined yield of about 27%. The synthesis depicted in Scheme 1 first couples 2-bromo-5,6-dichlorobenzimidazole with 1,2,3,5-tetra-O-acetyl-L-ribofuranose.
Implementation Method 2
an improved synthesis of maribavir in Scheme 5 with overall yields of at least 45%. It will be appreciated that the physical and/or chemical properties of certain intermediate compounds (e.g., compounds 2-3 or 5-8), solvents and/or reagents, as well as reaction conditions may contribute to the overall yield of maribavir and/or help control impurities, particularly when scaling-up the synthesis.
Implementation Method 3
Next, the acetyl groups are removed on the ribofuranose moiety followed by installation of the isopropylamine to provide maribavir.
Data Source
AI summary
The present disclosure discloses compositions comprising maribavir, methods of providing the same, and compositions providing intermediates useful in providing maribavir.